The first of a series of educational webinars on the latest developments in gene therapy for Gaucher treatment, focusing on AVROBIO's lentiviral gene therapy, an ex vivo gene therapy approach for Type 1 Gaucher disease, will take place on Monday 21st September from 3-4:30pm (GMT).
The main speaker will be AVROBIO's Chief Scientific Officer, Chris Mason and Prof Timothy Cox from Cambridge University will moderate.
Donation
Join us
Newsletter Subscription